๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

T-21 Effect of iron depletion on liver damage in nonalcoholic fatty liver disease: preliminary results of a randomized controlled trial

โœ Scribed by Valenti, L.; Fracanzani, A.L.; Dongiovanni, P.; Fatta, E.; Pulixi, E.A.; Maggioni, M.; Rovida, S.; Fargion, S.

Book ID
121888210
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
58 KB
Volume
45
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Betaine for nonalcoholic fatty liver dis
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
โœ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 227 KB ๐Ÿ‘ 2 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto

Correction: Betaine for nonalcoholic fat
Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial
โœ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 46 KB ๐Ÿ‘ 2 views

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.